This event will demonstrate how unique and transferable technical expertise in viral vector development can significantly accelerate the development path and future-proof gene therapy products.
This webinar, titled “Viral Vector Manufacturing Success Stories: Onboarding to GMP Production”, will feature a presentation by:
Amy Barker , PhD, Principal Scientist,Process Development atOxford Biomedica ,Andre Raposo , PhD, Director,Innovation Department atOxford Biomedica , andHannah Boss , Head of Quality Control atOxford Biomedica .
Attendees will learn about:
- Cutting-edge, end-to-end automation of analytical assays
- Design of Experiments to optimize vector production
- Considerations for product comparability during process changes
- Case studies to demonstrate enhancements to viral vector production and successful process transfer to GMP operations
The webinar will be held at
More information about Oxford Biomedica’s products and services can be found here.
-Ends-
About
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
Enquiries:
T: +44 (0)7519 109325 / E: partnering@oxb.com
Sophia Bolhassan, VP, Corporate Affairs and IR
T: +44 (0) 7394 562 425 / E: ir@oxb.com
ICR Consilium:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Source:
2024 GlobeNewswire, Inc., source